Psychedelic Research Chemicals or RC Chems are new synthetic substances which are structurally similar to the original drug, while being functional analogs. Data on their effects limited due as they’re fairly new and do not have a lot of human consumption history.

Psychedelics are substances (natural or laboratory made) which cause profound changes in a one’s perceptions of reality. While under the influence of hallucinogens, users might hallcuniate visually and auditorily.

This is an Experimental Substance with little data. This is most likely because the substance is is not very old. Information is limite and incomplete.

Disclaimer: Psychedelic drugs offer some of the most powerful and intense psychological experiences. Additionally these substances are illegal in many places. We understand that even though these substances are illegal, their use occurs frequently. We do not condone breaking of the law. By providing accurate information about these substances, we encourage the user to make responsible decisions and practice harm reduction.

Read the full disclaimer here.

Description

1B-LSD Also known as:

1B-LSD (1-butanoyl-lysergic acid diethylamide) is an LSD analogue which appears to be about as potent as 1P-LSD (slightly more potent than LSD) and has a slightly shorter duration than that of LSD, again thought to be about the same as 1P-LSD. Released in late 2018, and marketed agressively as a replacement for 1P-LSD. 1B-LSD does not yet have a clearly established safety profile,

Summary

1B-LSD is closely related to LSD and 1P-LSD and is reported to produce near-identical effects. Little is known about the pharmacology of 1B-LSD, but it likely produces its psychedelic effects by acting on serotonin receptors in the brain. The original synthesis date of 1B-LSD is unknown.

Unlike most research chemicals, 1B-LSD has no prior record in the scientific literature. The first reports of 1B-LSD use surfaced in 2018 following its appearance on the online research chemical market. User reports indicate that the subjective effects of 1B-LSD are extremely similar to those of 1P-LSD.

1B-LSD is theorized to act as a prodrug for LSD. The similarities in chemical structure between 1B-LSD and LSD predicts a near-identical effect profile, likely differing mainly in its rate of absorption and duration. Characteristics effects include geometric visual hallucinations, time distortion, enhanced introspection, and ego loss.

Its classical psychedelic effects and favorable tolerability has led it to become popular among novel psychoactive substance users who use it interchangeably with LSD. Very little data exists about the pharmacological properties, metabolism, and toxicity of 1B-LSD. It is presumed to have a similar toxicity and risk profile as LSD, although no evidence currently exists to support this.

It is highly advised to use harm reduction practices if using this substance.

History

A lucid argument can then be made that lysergic acid N,N-dimethylamide is derived from lysergic acid amide rather than LSD. Carrying this theme to the next logical step one would then assume that the 1-alkyl and 1-acyl derivatives of the N,N-dimethyl isomer would also not be controlled by the CsA amendment.— Donald A. Cooper, Future Synthetic Drugs of Abuse, 1988.

Chemistry

It is similar to LSD and is named for the butyryl group bound to the nitrogen of the polycyclic indole group of LSD. The tetracyclic ergoline is characteristic of the chemical structure of ergot alkaloids.

In contrast to LSD, 1B-LSD has an additional N1-butyryl group.

Chemical modifications in the N1 position are among the most frequently performed changes in the ergoline system, as the Indole nitrogen is easily accessible for alkylations, acylations, Mannich reactions and Michael additions.

Become an Exclusive Member For Free

Become a member now, sign up, and get free updates, news articles, and the latest happenings in the Psychedelic World.

Dose Chart

Oral
Light25-50ug
Common50-125ug
Strong125-250ug

Duration Chart

1B-LSD Duration Data
Onset45-90 minutes
Duration8-12 hours
After-effects6-24 hours

Legal Status

Internationally, 1B-LSD is not scheduled under the UN Convention on Psychotropic Substances. It is considered to exist in a legal grey area in many countries, meaning that while it is not specifically illegal, individuals may still be charged for its possession under certain circumstances such as under analogue laws and with the intent to sell or consume.

  • Austria: 1B-LSD is technically not illegal but it may fall under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD, thus making it illegal to supply for human consumption.

  • Germany: 1B-LSD is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
  • Latvia: 1B-LSD is illegal in Latvia. Although it is not officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1, 2015.
  • Lithuania: 1B-LSD is illegal in Lithuania and is specifically named on the list of illegal substances since June 5, 2019.
  • Sweden: Following its sale as a designer drug, 1B-LSD was made illegal in Sweden on January 26, 2016.
  • Switzerland: Legal status is uncertain and there is a significant chance it will be explicitly declared illegal on May 1, 2019 by Ordinance of the DFI on the lists of narcotic drugs, psychotropic substances, precursors and chemical adjuvants.
  • United Kingdom: 1B-LSD is illegal to produce, supply, or import under the Psychoactive Substance Act, which came into effect on May 26, 2016.
  • United States: Since 1B-LSD can be considered a prodrug for LSD, its possession and sale may be prosecutable in the United States under the Federal Analogue Act.

    • Sources

    References

    1. Brandt, S. D.; Kavanagh, P. V.; Westphal, F.; Stratford, A.; Elliott, S. P.; Hoang, K.; Wallach, J.; Halberstadt, A. L. (2015). "Return of the lysergamides. Part I: Analytical and behavioural characterization of 1‐propionyl‐d‐lysergic acid diethylamide (1P‐LSD)". Drug Testing and Analysis. 8 (9): 891–902. :10.1002/dta.1884.  1942-7603.
    2. "1B-LSD (Google Trends)". Retrieved January 1, 2020.
    3. Cooper, Donald A. (1988). "Future Synthetic Drugs of Abuse". Proceedings of the international symposium on the forensic aspects of controlled substances. p. 79.  978-0-93211-509-6.
    4. Wagmann, L.; Richter, L. H. J.; Kehl, T.; Wack, F.; Pettersson Bergstrand, M.; Brandt, S. D.; Stratford, A.; Maurer, H. H.; Meyer, M. R. (2019). "In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures". Analytical and Bioanalytical Chemistry. 411 (19): 4751–4763. :10.1007/s00216-018-1558-9.  1618-2642.
    5. Armstrong, B. D.; Paik, E.; Chhith, S.; Lelievre, V.; Waschek, J. A.; Howard, S. G. (2004). "Potentiation of (DL)‐3,4‐methylenedioxymethamphetamine (MDMA)‐induced toxicity by the serotonin 2A receptior partial agonist d‐lysergic acid diethylamide (LSD), and the protection of same by the serotonin 2A/2C receptor antagonist MDL 11,939". Neuroscience Research Communications. 35 (2): 83–95. :10.1002/nrc.20023.  1520-6769.
    6. Gudelsky, Gary A.; Yamamoto, Bryan; Nash, J. Frank (1994). "Potentiation of 3,4-methylenedioxymethamphetamine-induced dopamine release and serotonin neurotoxicity by 5-HT2 receptor agonists". European Journal of Pharmacology. 264 (3): 325–330. :10.1016/0014-2999(94)90669-6.  0014-2999.
    7. Capela, J. P.; Fernandes, E.; Remião, F.; Bastos, M. L.; Meisel, A.; Carvalho, F. (2007). "Ecstasy induces apoptosis via 5-HT2A-receptor stimulation in cortical neurons". Neurotoxicology. 28 (4): 868–875. :10.1016/j.neuro.2007.04.005.  0161-813X. PMID 17572501.
    8. Nichols, David E. (2004). "Hallucinogens". Pharmacology & Therapeutics. 101 (2): 131–181. :10.1016/j.pharmthera.2003.11.002.  0163-7258.
    9. Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. :10.1007/BF03161089.  1556-9039.
    10. "Synthetische Drogen: Neues Gesetz soll "Legal Highs" bekämpfen" [Synthetic drugs: New law is to combat legal highs] (in German). Der Standard. September 28, 2011. Retrieved January 1, 2020.
    11. "Entwurf: Bundesgesetz, mit dem ein Bundesgesetz über den Schutz vor Gesundheitsgefahren im Zusammenhang mit Neuen Psychoaktiven Substanzen (Neue-Psychoaktive-Substanzen-Gesetz, NPSG) erlassen und das Suchtmittelgesetz (SMG) geändert wird" (PDF) (in German). Retrieved January 1, 2020.
    12. "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
    13. "Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" (PDF). Bundesgesetzblatt Jahrgang 2019 Teil I Nr. 27 (in German). Bundesanzeiger Verlag. July 17, 2019. pp. 1083–1094. Retrieved January 1, 2020.
    14. "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz [Federal Ministry of Justice and Consumer Protection]. Retrieved December 10, 2019.
    15. "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" (in Latvian). VSIA Latvijas Vēstnesis. November 10, 2005. Retrieved January 1, 2020.
    16. "LR SAM Įsakymas Dėl Narkotinių ir psichotropinių medžiagų sąrašų patvirtinimo" (in Lithuanian). Retrieved January 1, 2020.
    17. "31 nya substanser klassas som narkotika eller hälsofarlig vara" (in Swedish). Folkhälsomyndigheten [Public Health Agency of Sweden]. January 26, 2016. Retrieved January 1, 2020.
    18. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
    19. "Psychoactive Substances Act 2016". UK Government. Retrieved January 1, 2020.

    Resources

    Information made possible with:

    1. PsychonautWiki is a community-driven online encyclopedia that aims to document the field of psychonautics in a comprehensive, scientifically-grounded manner.
    2. Erowid is a non-profit educational & harm-reduction resource with 60 thousand pages of online information about psychoactive drugs
    3. PubChem National Center for Bio Informatics
    4. Chemspider is a free chemical structure database providing fast access to over 34 million structures, properties and associated information.
    5. Wikipedia

    Additional APIs were used to construct this information. Thanks to ChemSpider, NCBI, PubChem etc.

    Data is constantly updated so please check back later to see if there is any more available information on this substance.